CD274 and aneurysmal bone cyst: Further, PD-1/PD-L1 is the target of antitumoral treatments after the survival results of the phase III study IMpassion130 / NCT0242589127 that supported the accelerated approval by the FDA of atezolizumab in combination with nabpaclitaxel for triple negative ABC with PD-L1 expression.